Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Drug interactions and new antidepressive agents]

B Bonin1, S Vandel

  • 1Service de Psychiatrie et Psychologie Médicale, CHU St. Jacques, Besançon, France.

Therapie
|May 1, 1995
PubMed
Summary

New antidepressants like fluoxetine, fluvoxamine, and paroxetine inhibit serotonin reuptake. They frequently interact with tricyclic antidepressants, increasing plasma levels and side effects due to cytochrome P450 inhibition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Catatonia education in France: A cross-sectional study].

L'Encephale·2019
Same author

Type A competitiveness traits correlate with downregulation of c-Fos expression in patients with type 1 diabetes.

Diabetes & metabolism·2018
Same author

Type A personality is not associated with poor glycaemic control: Data from cross-sectional and longitudinal surveys of people with type 1 or type 2 diabetes.

Diabetes & metabolism·2016
Same author

Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis.

Molecular psychiatry·2016
Same author

Potential influence of Type A personality on plasma C-reactive protein levels in people with diabetes.

Diabetes & metabolism·2015
Same author

Low frequency transcranial magnetic stimulation downregulates expression of stress genes in blood leucocytes: preliminary evidence.

Journal of psychiatric research·2013

Area of Science:

  • Pharmacology
  • Neuroscience

Context:

  • Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed.
  • Drug interactions are a significant concern in psychopharmacology.

Purpose:

  • To review and report on the interactions between new serotonergic antidepressants and commonly co-prescribed drugs.
  • To elucidate the pharmacokinetic and pharmacodynamic aspects of these drug interactions.

Summary:

  • New antidepressants, including fluoxetine, fluvoxamine, and paroxetine, selectively inhibit serotonin reuptake.
  • Literature review indicates frequent and significant interactions with tricyclic antidepressants.
  • These interactions often lead to elevated tricyclic drug plasma levels and adverse effects, primarily due to SSRI inhibition of cytochrome P450 enzymes.

Impact:

  • Highlights the clinical significance of drug-drug interactions in antidepressant therapy.
  • Provides insights into the pharmacokinetic mechanisms underlying these interactions.
  • Informs prescribing practices to mitigate potential adverse events associated with combined antidepressant therapy.

Related Experiment Videos